• Pre-operative evaluation of patients with Type 2 Diabetes Mellitus (T2DM) undergoing Roux-en-Y Gastric Bypass (RYGB).
• Predicting the probability of complete T2DM remission (HbA1c < 6.5% and fasting glucose < 126 mg/dL without medication) at 5 years post-surgery.
• Assisting in shared decision-making regarding the metabolic benefits of bariatric surgery.

The DiaRem score is heavily weighted by insulin use (10 points). This reflects advanced beta-cell exhaustion; patients already requiring insulin have a significantly lower physiological ceiling for surgical "remission" compared to those managed with oral agents alone.

• Simpler to calculate at the bedside than the ABCD score as it does not require C-peptide levels.
• High negative predictive value: A score > 18 strongly suggests the patient will require ongoing diabetes management despite significant weight loss.
• Helps manage patient expectations: Patients in Group 4 should be told surgery is for "improvement" rather than "cure".

• Does not account for duration of diabetes (unlike the ABCD or Advanced DiaRem scores).
• Lower accuracy in patients with BMI < 35 kg/m2.
• Originally derived from a primarily Caucasian cohort; may require adjustment for other ethnicities.

• Low Score (0–7): Counsel that RYGB has a high likelihood of eliminating the need for T2DM medications.
• Intermediate Score (8–17): Discuss that while glucose control will improve, the need for some oral medications may persist.
• High Score (≥ 18): Clarify that surgery is indicated for weight loss and CVD risk reduction, but T2DM remission is unlikely.
• Compare with ABCD Score: If C-peptide is available, use the ABCD score for a more granular physiological assessment.

The DiaRem score was developed by researchers at the Geisinger Health System (Pennsylvania, USA). The goal was to create a tool using only standard, readily available clinical parameters that insurance companies and surgeons could use to quantify the metabolic benefits of RYGB.

Historically, "Diabetes Surgery" was a binary concept. The DiaRem developers recognized that T2DM is a progressive disease of beta-cell failure and that surgical outcomes are highly dependent on the "point of no return" regarding pancreatic function.